검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | semaglutide (Ozempic / Wegovy, GLP-1, Wegovy, NN9535) Novo Nordisk·GLP-1 receptor Weight ↓14.9%·t½ ~1 week (SC) |
|---|---|
Overview Program | Ozempic / Wegovy (semaglutide) |
Overview Company | Novo Nordisk |
Overview Modality | ANTIBODY |
Overview Target | GLP-1 receptor |
Overview Indication | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) |
Overview Phase | APPROVED |
Overview Status | APPROVED |
MoA Mechanism | GLP-1R agonism → glucose-dependent insulin secretion, delayed gastric emptying, central satiety |
MoA Biomarker | HbA1c, body weight, waist circumference |
PK/PD Half-life | ~1 week (SC) |
PK/PD Species | Mouse, HbA1c, fasting glucose, weight |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | NHP, Mouse, Rat |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic |
Toxicology CRS | N/A |
Clinical Primary efficacy | Weight ↓14.9% |
Clinical ORR | Weight ↓14.9% vs placebo (STEP 1) |
Clinical PFS | MACE benefit in SELECT (obesity + CVD) |
Clinical Result source | STEP 1 / SELECT |
Clinical Data Tier / Score | A · 75 |
Clinical Program phase | APPROVED |
Clinical Dose / schedule | q1w SC (titrated) or oral daily |
Clinical Clinical sync | 2026년 7월 20일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | semaglutide (Ozempic / Wegovy, GLP-1, Wegovy, NN9535) Novo Nordisk·GLP-1 receptor Weight ↓14.9%·t½ ~1 week (SC) |
|---|---|
Overview Program | Ozempic / Wegovy (semaglutide) |
Overview Company | Novo Nordisk |
Overview Modality | ANTIBODY |
Overview Target | GLP-1 receptor |
Overview Indication | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) |
Overview Phase | APPROVED |
Overview Status | APPROVED |
MoA Mechanism | GLP-1R agonism → glucose-dependent insulin secretion, delayed gastric emptying, central satiety |
MoA Biomarker | HbA1c, body weight, waist circumference |
PK/PD Half-life | ~1 week (SC) |
PK/PD Species | Mouse, HbA1c, fasting glucose, weight |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | NHP, Mouse, Rat |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic |
Toxicology CRS | N/A |
Clinical Primary efficacy | Weight ↓14.9% |
Clinical ORR | Weight ↓14.9% vs placebo (STEP 1) |
Clinical PFS | MACE benefit in SELECT (obesity + CVD) |
Clinical Result source | STEP 1 / SELECT |
Clinical Data Tier / Score | A · 75 |
Clinical Program phase | APPROVED |
Clinical Dose / schedule | q1w SC (titrated) or oral daily |
Clinical Clinical sync | 2026년 7월 20일 (1일 전) |
추천 비교
추천 비교